Using shRNA targeting MAP3K8 or MAP3K8 kinase inhibitor, we have demonstrated for the first time that MAP3K8 positively controls ovarian cancer cell proliferation, migration and invasion, as well as tumour growth in mouse models. Here, MAP3K8 is linked to ovarian cancer.